Current Report Filing (8-k)
June 19 2020 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
June 17, 2020
Fortress Biotech, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
(State or Other Jurisdiction
of Incorporation)
|
|
001-35366
(Commission File Number)
|
|
20-5157386
(IRS Employer Identification No.)
|
2 Gansevoort Street, 9th Floor
New York, New York 10014
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act.
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act.
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2b
under the Exchange Act.
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act.
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
FBIO
|
Nasdaq Capital Market
|
9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
|
FBIOP
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As described under Item 5.07 of this report,
on June 17, 2020, the stockholders of Fortress Biotech, Inc. (the “Company” or “Fortress”) voted at the
Company’s 2020 annual meeting of stockholders (the “2020 Annual Meeting”) to approve an amendment (the “Plan
Amendment”) to the Company’s 2013 Stock Incentive Plan (the “Incentive Plan”) to increase the shares of
common stock available for issuance under the Incentive Plan by 3,000,000 shares from 10,000,000 shares to 13,000,000 shares.
The Company’s Board of Directors
approved the Plan Amendment on April 22, 2020, subject to stockholder approval at the 2020 Annual Meeting. The Plan Amendment became
effective at the time of stockholder approval.
A copy of the Plan Amendment is filed as
Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 5.02. The material terms of the Incentive
Plan as so amended are described in the Company’s definitive proxy statement on Schedule 14A for the 2020 Annual Meeting
filed with the Securities and Exchange Commission (the “SEC”) on April 27, 2020.
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
As described under Item 5.07 of this report,
on June 17, 2020, the stockholders of the Company voted at the 2020 Annual Meeting to approve amendment to the Company’s
Amended and Restated Certificate of Incorporation to (i) increase the number of shares of common stock authorized for issuance
by 50,000,000 shares, bringing the total number of authorized shares of common stock to 150,000,000 shares (the “Authorized
Shares Amendment”) and (ii) increase the frequency of the dividend payments on the Company’s 9.375% Series A Cumulative
Redeemable Perpetual Preferred Stock from quarterly to monthly (the “Perpetual Preferred Dividend Frequency Amendment”).
On June 18, 2020, following the 2020 Annual
Meeting, the Company filed certificates of amendment giving effect to each of the Authorized Shares Amendment and the Perpetual
Preferred Dividend Frequency Amendment with the Secretary of State of the State of Delaware. Copies of each certificate of amendment
giving effect to the Authorized Shares Amendment and the Perpetual Preferred Dividend Frequency Amendment are filed as Exhibit
3.1 and Exhibit 3.2, respectively, to this Current Report on Form 8-K and is incorporated by reference in this Item 5.03.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 17, 2020, the Company held its
2020 Annual Meeting of stockholders at 10:00 a.m. Eastern Time by means of an online virtual meeting platform. Stockholders representing
69,449,768 shares of the Company’s common stock, or 85.32%, of the 81,391,206 shares entitled to vote, were represented in
person or by proxy, constituting a quorum.
At the 2020 Annual Meeting, the following
four proposals were approved: (i) the election of eight directors to hold office until the 2021 annual meeting; (ii) an amendment
to Fortress’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized
for issuance by 50,000,000 shares from 100,000,000 shares to 150,000,000 shares; (iii) an amendment to Fortress’s Amended
and Restated Certificate of Incorporation to increase the frequency of the dividend payments on the Company’s 9.375% Series
A Cumulative Redeemable Perpetual Preferred Stock from quarterly to monthly; (iv) an amendment to the Incentive Plan to increase
the shares of common stock available for issuance under the Incentive Plan by 3,000,000 shares from 10,000,000 to 13,000,000; and
(v) the ratification of the appointment of BDO USA, LLP as Fortress’s independent registered public accounting firm for the
year ending December 31, 2020. The five proposals are described in detail in Fortress’s definitive proxy statement on Schedule
14A for the 2020 Annual Meeting filed with the SEC on April 27, 2020.
Proposal 1
The votes with respect to the election
of eight directors to hold office until the 2021 annual meeting were as follows:
Director
|
Votes For
|
% Voted For
|
Votes Withheld
|
% Voted Withheld
|
Broker Non-Votes
|
Lindsay A. Rosenwald, M.D.
|
49,455,415
|
99.43%
|
284,125
|
0.57%
|
19,710,228
|
Michael S. Weiss
|
48,614,201
|
97.74%
|
1,125,339
|
2.26%
|
19,710,228
|
Eric R. Rowinsky, M.D.
|
49,325,247
|
99.17%
|
414,293
|
0.83%
|
19,710,228
|
J. Jay Lobell
|
44,813,456
|
90.10%
|
4,926,084
|
9.90%
|
19,710,228
|
Jimmie Harvey, Jr., M.D.
|
49,325,519
|
99.17%
|
414,021
|
0.83%
|
19,710,228
|
Dov Klein
|
48,753,669
|
98.02%
|
985,871
|
1.98%
|
19,710,228
|
Malcolm Hoenlein
|
48,994,295
|
98.50%
|
745,245
|
1.50%
|
19,710,228
|
Kevin L. Lorenz, J.D.
|
45,895,659
|
92.27%
|
3,843,881
|
7.73%
|
19,710,228
|
Proposal 2
The vote with respect to the approval of
an amendment to Fortress’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock
authorized for issuance by 50,000,000 shares from 100,000,000 shares to 150,000,000 shares was as follows:
Total Votes For
|
Total Votes Against
|
Abstentions
|
Broker Non-Votes
|
67,539,139
|
1,729,834
|
180,795
|
0
|
Proposal 3
The vote with respect to the approval of
an amendment to Fortress’s Amended and Restated Certificate of Incorporation to amend the Certificate of Designations of
Rights and Preferences of the Company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock to increase the frequency
of the dividend payments on the Company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock from quarterly
to monthly was as follows:
Total Votes For
|
Total Votes Against
|
Abstentions
|
Broker Non-Votes
|
48,980,516
|
705,999
|
53,025
|
19,710,228
|
Proposal 4
The vote with respect to the approval of
an amendment to Fortress’s 2013 Stock Incentive Plan was as follows:
Total Votes For
|
Total Votes Against
|
Abstentions
|
Broker Non-Votes
|
47,704,074
|
1,891,114
|
144,352
|
19,710,228
|
Proposal 5
The vote with respect to the ratification
of BDO USA, LLP as Fortress’s independent registered accounting firm for the year ending December 31, 2020 was as follows:
Total Votes For
|
Total Votes Against
|
Abstentions
|
Broker Non-Votes
|
69,264,727
|
119,265
|
65,776
|
0
|
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
The following exhibits are filed as part of this report:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Fortress Biotech, Inc.
|
|
(Registrant)
|
|
|
|
|
|
|
Date: June 19, 2020
|
|
|
|
By:
|
/s/ Lindsay A. Rosenwald, M.D.
|
|
|
|
Lindsay A. Rosenwald, M.D.
|
|
|
|
Executive Chairman, President and Chief Executive Officer
|
|
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024